Items where authors include "Seligmann, J"

Article

Platt, JR, Williams, CJM orcid.org/0000-0002-1574-653X, Craig, Z et al. (4 more authors) (2023) Personalising Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer: Protocols for the International Phase III FOxTROT2 and FOxTROT3 Randomised-Controlled Trials. Colorectal Disease. ISSN 1462-8910

Cervantes, A, Adam, R, Roselló, S et al. (8 more authors) (2023) Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34 (1). pp. 10-32. ISSN 0923-7534

Hudson, EM orcid.org/0000-0001-8758-7163, Noutch, S, Brown, S orcid.org/0000-0002-7975-7537 et al. (19 more authors) (2022) A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial. BMJ Open, 12 (4). e049119. ISSN 2044-6055

Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745

Randon, G, Yaeger, R, Hechtman, JF et al. (23 more authors) (2021) EGFR Amplification in Metastatic Colorectal Cancer. Journal of the National Cancer Institute (JNCI), 113 (11). pp. 1561-1569. ISSN 0027-8874

Hoorn, ST, Sommeijer, DW, Elliot, F et al. (12 more authors) (2021) Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer. ISSN 0007-0920

Adams, R, Brown, E, Brown, L et al. (14 more authors) (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3 (3). pp. 162-171. ISSN 2468-1253

Afshar, M, Hamilton, P, Seligmann, J et al. (5 more authors) (2015) Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)? Cancer Investigation, 33 (8). ISSN 0735-7907

Book Section

Seligmann, J, Messenger, M orcid.org/0000-0002-4975-0158, Seymour, M et al. (1 more author) (2017) Clinical Trials in Precision Oncology. In: Copson, ER, Hall, P, Board, RE, Cook, G and Selby, P, (eds.) Problem Solving Through Precision Oncology: A Case Study Based Reference and Learning Resource. Clinical Publishing , Abingdon, Oxon, UK . ISBN 978-1-84692-111-7

Conference or Workshop Item

Richman, SD orcid.org/0000-0003-3993-5041, Williams, CJM orcid.org/0000-0002-1574-653X, West, NP orcid.org/0000-0002-0346-6709 et al. (18 more authors) (2020) The N6 Consortium: The Northern Pathology Network. In: 2020 Joint Winter Meeting with RSM, 21-22 Jan 2020, London, UK.

Proceedings Paper

Battisti, NML, Wallington, M, Ring, A et al. (12 more authors) (2018) Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: A national registry study. In: Annals of Oncology. 43rd ESMO Congress (ESMO 2018), 19-23 Oct 2018, Munich, Germany. Oxford University Press .

Richman, SD orcid.org/0000-0003-3993-5041, Adams, R, Brown, E et al. (14 more authors) (2017) FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, bRAF and PIK3CA. In: Journal of Pathology. Belfast Pathology 2017: 10th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 20-23 Jun 2017, Belfast, Northern Ireland, UK. Wiley , S13-S13.

Seligmann, J, Wood, H orcid.org/0000-0003-3009-5904, Richman, S orcid.org/0000-0003-3993-5041 et al. (6 more authors) (2017) 545P Epidermal growth factor receptor (EGFR) copy number (CN) as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC). In: Annals of Oncology. 42nd ESMO Congress (ESMO 2017), 08-12 Sep 2017, Madrid, Spain. Oxford University Press , p. 185.

Turnbull, S, West, E, Scott, K orcid.org/0000-0002-5790-9579 et al. (5 more authors) (2017) Revealing potential immune responses (IRs) in patients with advanced colorectal cancer (aCRC) on first line chemotherapy: A prospective study of neutrophil to lymphocyte ratio, immune function and outcome. In: Annals of Oncology. ESMO 2017 Congress, 08-12 Sep 2017, Madrid, Spain. Oxford University Press .

Adams, RA, Brown, E, Brown, L et al. (13 more authors) (2016) FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS. In: Annals of Oncology. 41st ESMO Congress (ESMO 2016), 07-11 Oct 2016, Copenhagen. Oxford University Publishing .